First participants enrolled in the Karma CREME-1 study.

The Karma CREME-1 phase 2 clinical trial on topical endoxifen for preventive treatment of women with mammographic breast density is now open for inclusion. The study will include 90 participants and each participant will use topical endoxifen for six months. Preliminary results are expected during spring 2019.

Comments are closed.